Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ila Exploratory 2-stage Design Study of CPC634 (CriPec® Docetaxel) Monotherapy in Subjects With Platinum Resistant Ovarian Cancer.

NCT03742713 is registered in ClinicalTrials.gov with Cristal Therapeutics as lead sponsor.

NCT NCT03742713
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03742713 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ila Exploratory 2-stage Design Study of CPC634 (CriPec® Docetaxel) Monotherapy in Subjects With Platinum Resistant Ovarian Cancer.
Lead sponsor
Cristal Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
October 1, 2018
Completion date
December 1, 2020
Enrollment
25 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, ovarian cancer